1-Cyclobutylidene-2-methylpropane-2-sulfinamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 亚磺酸及其衍生物
• 英文名称: 1-Cyclobutylidene-2-methylpropane-2-sulfinamide
• 英文别名: 1-cyclobutylidene-2-methylpropane-2-sulfinamide
• 化学式: C₈H₁₅NOS
• 分子量: 173.28
• InChiKey: KYAIIXHBLJZXFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  62.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES DE L'ACÉTYLCHOLINE M1
  申请人：PIPELINE THERAPEUTICS INC

  公开号：WO2021071843A1

  公开（公告）日：2021-04-15

  Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

  本文提供了一些化合物，这些化合物可用作胆碱能乙酰胆碱受体M1（mAChR M1）的拮抗剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与胆碱能乙酰胆碱受体功能障碍相关的神经和精神疾病的方法。
• [EN] FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE PENTACYCLIQUES FUSIONNÉS
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2016050975A1

  公开（公告）日：2016-04-07

  A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[l,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

  一系列融合的五环咪唑衍生物，作为人类TNFa活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和伤害感知性疾病；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。特别是，本发明涉及6,7-二氢-7,14-甲基苯并咪唑[1,2-b][2,5]苯并二氮杂环-5(14H)-酮衍生物及其类似物。
• [EN] DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] DIHYDROPYRROLIDINOPYRIMIDINES COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2014047020A1

  公开（公告）日：2014-03-27

  The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERKl and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics

  本发明提供了式(I)的化合物及其药用盐；如本文所述。本发明进一步提供了包含这些化合物的药物组合物，以及与治疗协同剂结合或使用的这些化合物的组合物，以及这些化合物和组合物的治疗用途。这些在治疗与ERKl和/或ERK2激活相关的癌症等疾病方面非常有用，特别适用于对Raf和/或MEK抑制癌症治疗药物显示抵抗的MAPK信号通路依赖性癌症。
• NAMPT INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP2847192A1

  公开（公告）日：2015-03-18
• DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2897961A1

  公开（公告）日：2015-07-29